Affymetrix Appoints Robert Trice to Board of Directors
February 15 2006 - 8:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) announced today that Robert H. Trice,
Ph.D., senior vice president for business development at Lockheed
Martin Corporation and chairman and CEO of Lockheed Martin Global
Inc., has been elected to the company's board of directors. "We are
pleased to add Dr. Trice to the company's board," said Stephen P.A.
Fodor, Ph.D., chairman and CEO at Affymetrix. "His management
experience and international business development expertise will be
invaluable as we continue to expand into new markets around the
world." "Affymetrix GeneChip(R) microarray technology has quickly
become the gold standard in academia and in hundreds of leading
pharmaceutical, biotechnology, diagnostics and consumer product
companies," said Dr. Trice. "I look forward to being a part of this
organization as we explore new markets with innovative products to
accelerate scientific research and improve patient care." Trice is
currently responsible for worldwide new business strategies and
operations at Lockheed Martin Corp. as well as the overall business
direction at Lockheed Martin Global. Since joining Lockheed Martin
in 1996, he has held several senior management positions and
overseen many international aspects of the business. Before that
Trice served as vice president and general manager for business
development at McDonnell Douglas Aerospace for six years. Trice is
a member of the board of advisors for The Thomas Jefferson Program
in Public Policy at the College of William and Mary, as well as the
board of visitors of the La Follette School of Public Affairs and
the Department of Political Science at the University of
Wisconsin-Madison. He is a member of the Council on Foreign
Relations and Board of Supporters of Civil Society in Russia. He
also serves as co-chairman of the US-Danish Business Council. In
addition, Trice is an associate fellow of the American Institute of
Aeronautics and Astronautics, and past chairman of the
International Council of the Aerospace Industries Association.
Trice holds a bachelor's degree from the College of William and
Mary and master's and doctorate degrees in political science from
the University of Wisconsin-Madison. Dr. Trice is the author of
numerous works on American foreign policy and defense industrial
issues. About Affymetrix: Affymetrix scientists invented the
world's first microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip(R)
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,300 systems have been installed around the
world and nearly 4,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with subsidiaries in Europe and Asia, as well as
manufacturing facilities in Sacramento, Calif., and Bedford, Mass.
The company has about 1,000 employees worldwide. For more
information about Affymetrix, please visit the company's Web site
at www.Affymetrix.com. All statements in this press release that
are not historical are "forward-looking statements" within the
meaning of Section 21E of the Securities Exchange Act as amended,
including statements regarding Affymetrix' "expectations,"
"beliefs," "hopes," "intentions," "strategies" or the like. These
include statements related to the value of Dr. Robert Trice's
experience and expertise to Affymetrix, which are prospective. Such
statements are subject to risks and uncertainties that could cause
actual results to differ materially for Affymetrix from those
projected, including, but not limited to: risks of the Company's
ability to achieve and sustain higher levels of revenue, higher
gross margins, reduced operating expenses; uncertainties relating
to technological approaches, manufacturing (including risks related
to the Company's ability to achieve hoped-for manufacturing yields
for certain array products, including the ability to identify and
resolve manufacturing problems), product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties
relating to sole source suppliers; uncertainties relating to FDA
and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31,
2004 and other SEC reports, including its Quarterly Reports on Form
10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix' expectations with
regard thereto or any change in events, conditions, or
circumstances on which any such statements are based.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024